/
Oncology
Salivary Gland Cancer
31
Pipeline Programs↗
16
Active Trials↗
22
Companies Involved↗
Salivary Gland Cancer is a moderately active landscape with 31 programs across 22 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical12
Phase 1
No programs
Phase 219
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
23 of 30 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 97% of 31 pipeline programs.
Analysis
Trial Status
45
clinical trials
Completed19 · 42%
Active, not recruiting8 · 18%
Recruiting7 · 16%
Unknown status5 · 11%
Terminated4 · 9%
Not yet recruiting1 · 2%
Other1 · 2%
Clinical Trials
Trial Activity
45 trials
A Prospective, Open-Label, Single-Arm, Phase II Clinical Study of Abiraterone Combined With Dalpiciclib in Patients With HER-2-Negative, AR-Positive Recurrent/Metastatic Salivary Gland Carcinoma
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07815522·36 enrolled
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Recruiting·—·Phase 2·NCT04620187·55 enrolled
Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma
Recruiting·—·Phase 2·NCT05727410·50 enrolled
A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma
Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Preclinical·NCT03781986·41 enrolled
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Active, not recruiting·—·Phase 2·NCT03942653·20 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)